R&D | December 05, 2025
DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Several technologies for hemoglobinopathies are being transferred to commercial partners
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated
